Abstract:Concurrent chemoradiation (CCR) with cisplatin plus 5-Fu (PF) regimen is a standard modality for locally advanced esophageal squamous cell carcinoma (ESCC) patients. This trial aimed to assess the efficacy and safety of the paclitaxel plus 5-Fu (TF) regimen versus PF regimen in CCR for ESCC patients. ESCC patients presenting with stage IIa to IVa were enrolled in a prospective multicenter randomized phase 3 study. Patients were randomized to either TF or PF group. Patients in TF group were treated with 5 cycles of weekly TF (5-Fu 300 mg/m2, civ 96h plus paclitaxel 50 mg/m2, d1) in CCR followed by 2 cycles of monthly TF (5-FU 1800 mg/m2, civ 72h, plus paclitaxel 175 mg/m2 d1) in consolidation chemotherapy. Patients in PF group were treated with 2 cycles of CCR followed by 2 cycles of consolidation chemotherapy with PF (cisplatin 25 mg/m2/d, d1-3, plus 5-Fu 1800 mg/m2, civ 72h, q28d). The radiation therapy dose was 61.2 Gy delivered in 34 fractions. The primary end-point was the 3-yr overall survival (OS). The secondary endpoints were disease progression-free survival (DPFS), local progression-free survival (LPFS), and number and grade of participants with adverse events. This trial was registered with ClinicalTrials.gov, number NCT01591135. Four hundred thirty-six ESCC patients (217 assigned to TF group and 219 assigned to PF group) in 6 centers were recruited between April 2012 and July 2015. Median follow-up of patients who survived was 44.6 months [IQR 29.3–72.0]. The 3-yr OS was 57% in TF group and 51% in PF group (HR 0.91; 95% CI 0.69-1.18; P = 0.46). No significant differences were recorded in 3-yr DPFS or 3-yr LPFS between TF and PF groups (44.3% vs. 45.3% and 48.8% vs. 49.8%, respectively). TF group had a significant higher incidence of acute Grade 3/4 leukopenia (31.3% vs. 18.3%), dermatitis (5.1% vs. 1.4%), and pneumonitis (9.7% vs. 3.2%), and significant lower incidence of anemia (0.5% vs. 3.2%), thrombocytopenia (0.5% vs. 13.7%), fatigue (6.9% vs. 19.6%), anorexia (1.4% vs. 14.6%), nausea (1.4% vs. 14.2%), and vomiting (2.3% vs. 18.3%) than PF group (P < 0.05). There were 3 (1.4%) patients in TF group died of acute pneumonitis. For long-term adverse events, 1 (0.5%) patient in TF group and 2 (0.9%) patients in PF group died of delayed pneumonitis. TF might be an option used in CCR in ESCC patients with a different type of side effects compared with PF, although it did not significantly prolong OS.

Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil

Effect of the combination of Elemene and concurrent chemoradiation with cisplatin followed by consolidation chemotherapy with cisplatin and fluorouracil for locally advanced esophageal cancer

Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome

Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer

Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma

Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial

Concurrent Three Dimensional Conformal Radiotherapy and Chemotherapy with DF Regime in the Treatment for 33 Cases with Advanced Esophageal Carcinoma

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin Versus 5-Fluorouracil Plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma

Concurrent Cisplatin And 5-Fluorouracil Versus Concurrent Cisplatin And Docetaxel With Radiotherapy For Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis

Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.

Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.

Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer

Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial

A Phase II Study of Neoadjuvant Chemoradiotherapy with Docetaxel, Cisplatin and 5-FU Followed by Surgical Resection in the Treatment of Locally Advanced Esophagogastric Junction Cancer and Locally Advanced Esophageal Cancer

Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study

Final Results of a Phase 3 Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma

[Phase II Clinical Trial of Concurrent Chemoradiotherapy (cisplatin Plus 5-Fluorouracil) for Esophageal Cancer].

Paclitaxel and Carboplatin Versus Cisplatin and 5-Fluorouracil in Concurrent Chemoradiotherapy in Patients With Esophageal Cancer

Final Results of a Phase 3 Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma (Eso-Shanghai 1).

Concurent Chemotherapy Combined with Late Course Accelerated Hyperfractionated Radiotherapy for Advanced Esophageal Carcinoma

A Randomized, Controlled Phase III Trial of Docetaxel, Cisplatin and Fluorouracil (DCF) versus Cisplatin Plus Fluorouracil (CF) as First-Line Therapy in Chinese advanced Gastric Cancer